A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro, in vivo and clinical data identifies the importance of modulation of the mTORC1 pathway-Reference-Cited by-同舟云学术

A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro, in vivo and clinical data identifies the importance of modulation of the mTORC1 pathway

Published:2015-10-19 Issue:39 Volume:6 Page:41736-41749
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Cheraghchi-Bashi Azadeh¹²,Parker Christine A.²³,Curry Ed¹,Salazar Jean-Frederic²,Gungor Hatice⁴,Saleem Azeem²⁴,Cunnea Paula¹,Rama Nona⁴,Salinas Cristian²,Mills Gordon B.⁵,Morris Shannon R.⁶,Kumar Rakesh⁷,Gabra Hani¹,Stronach Euan A.¹

Affiliation:

1. Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, Hammersmith Campus, London, UK

2. GlaxoSmithKline, Clinical Imaging Centre, Hammersmith Hospital, London, UK

3. Division of Experimental Medicine, Centre for Neuroscience, Imperial College, London, UK

4. Department of Surgery and Cancer, Faculty of Medicine, Imperial College, London, UK

5. The University of Texas MD Anderson Cancer Center, Houston, TX, USA

6. GlaxoSmithKline, Oncology R&D, Research Triangle Park, NC, USA

7. GlaxoSmithKline, Oncology R&D, Collegeville, PA, USA

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacoproteomics and Drug Delivery Strategies for Cancer Nanomedicines;Pharmacoproteomics;2024

2. Inhibitors of phosphoinositide 3-kinase (PI3K) and phosphoinositide 3-kinase-related protein kinase family (PIKK);Journal of Enzyme Inhibition and Medicinal Chemistry;2023-07-24

3. Vibsane-type diterpenoids from Viburnum odoratissimum inhibit hepatocellular carcinoma cells via the PI3K/AKT pathway;Phytomedicine;2023-01

4. Akt: a key transducer in cancer;Journal of Biomedical Science;2022-10-01

5. Akt inhibitors in cancer therapy;Protein Kinase Inhibitors;2022